June 11, 2026 2026 Q2 Economic Factors and J&J Announcements Below is a high-level summary of current macro-economic factors, notable announcements made this quarter, as well as public commentary made by management during the quarter and recent earnings calls. Any additional information included herein is provided as phasing considerations and should not be construed as guidance. Phasing considerations: As a reminder, please note the following: • The impact of the Intra-Cellular benefit laps in Q2. • In 2026, we benefit from a 53 rd week in our financial calendar, which is worth approximately 100 basis points to full year sales growth and neutral to bottom line due to expenses for an additional week. • We expect heavier investment in the first half of the year. • For your convenience, as we progress through 2026, we have attached QTD and FY segment P&Ls for 2025. Macro-economic factors: • Interest Rates: The Federal Funds Rate continues to impact the financing cost of our commercial paper as well as interest income on our cash position. • Tariffs: In Q4 we noted a 2026 approximate impact of $500MM, exclusively related to our MedTech business, based on tariff information known at the time. We are reviewing the impact of the Supreme Court’s decision to deny the IEEPA tariff authority, the outcomes of recent hearings, and the implementation of new tariffs through Section 122 at a flat 10%. We will provide further guidance as we have additional clarity on the financial impact of these decisions and will continue to monitor tariffs and their potential impact to our business. • Global Affairs: As described in our Form 10-K risk factors, we have experienced, and expect to continue to experience, impacts to the Company's business resulting from the Russia-Ukraine war, conflict in the Middle East as well as increasing tensions between the U.S. and China. • Foreign Exchange: We do not offer guidance or predictions on currency movements, but as highlighted by Joe during the Q1 2026 earnings call, we utilized the Euro Spot Rate relative to the U.S. dollar of 1.17. The Euro -- 1 of 6 -- Spot Rate averaged 1.17 in April, 1.17 in May, compared to a current spot rate of approximately 1.15 over the past few days. As a reminder, our results are based on a basket of currencies, of which, not all align to the Euro. Conference participation J&J conference participation (transcripts and webcasts) throughout the quarter can be found here. Transcripts for the events below have been attached for your convenience. • Bank of America 2026 Healthcare Conference: John Reed – Executive Vice President - Pharmaceuticals, R&D fireside chat with Jason Gerberry - Bofa Merrill Lynch Asset Holdings Inc - Analyst • 2026 RBC Capital Markets Global Healthcare Conference: Michael Bodner – Company Group Chair, Electrophysiology & Neurovascular, fireside chat with Shagun Singh - RBC Capital Markets Inc - Analyst • Bernstein’s 42nd Annual Strategic Decisions Conference: Joaquin Duato – Chairman of the Board, Chief Executive Officer, fireside chat with Lee Hambright – Sanford C Bernstein & Co LLC – Analyst • Goldman Sachs 47th Annual Global Healthcare Conference: Tom Cavanaugh– Group Chairman Innovative Medicine, North America, fireside chat with Asad Haider – Goldman Sachs - Managing Director -- 2 of 6 -- Announcements Press releases issued during the quarter can be found on the J&J Media Center, Innovative Medicine Newsroom, and MedTech News & Events page. • M&A: Firefly Bio, Inc. Acquisition; Atraverse Medical, Inc. Acquisition • Talc: please visit factsabouttalc.com for the latest company statements • Enterprise: Generation Fine Campaign; Ryan Koors- VP of J&J IR Announcement • Innovative Medicine: o CAPLYTA: APA and ASCP long-term data in MDD; First network meta-analysis results; Supplemental New Drug Application FDA Approval o ERLEADA: Phase 3 PROTEUS study o ICOTYDE: Phase 3 ICONIC-ADVANCE 1 and 2 and ICONIC-LEAD studies o IMAAVY: FDA grants Priority Review wAIHA; Phase 3 Vivacity-MG3 study; Phase 2/3 study (wAIHA) o INLEXZO: Standard-of-care bladder cancer survey; Permanent Billing Code o JNJ-4804: Phase 2b data results o Nipocalimab: SLE Phase 2 results; Phase 2 DAHLIAS Sjögren's disease results; o RYBREVANT + LAZCLUZE: Phase 1/1b CHRYSALIS-2 study NSCLC o RYBREVANT FASPRO: Phase 1b/2 OrigAMI-4 study o TECVAYLI: Phase 3 MajesTEC-9 study o TREMFYA: FDA label expansion approval sBLA; Phase 3 FUZION study • MedTech: o Shockwave: Shockwave™ C2 Aero Coronary IVL Catheter Launch o OTTAVA: Clinical Study Results for a New Soft-Tissue Surgical Robotic System o EP: CARTOSOUND SONATA Module launch HRS 2026; Launch of VARIPULSE Pro in Europe following CE Mark approval o Vision: ASCRS 2026 New Clinical Data for TECNIS PureSee IOL; Expanded U.S. Availability of TECNIS PureSee IOL o Orthopaedics: Miniature Radiofrequency Tracking Technology Acquisition; CGBIO distribution agreement -- 3 of 6 -- J&J earnings calls: • Q1 2026 earnings call: Full year 2026 Operational Sales Guidance of $99.7B - $100.7B or 5.9% - 6.9% and Adjusted Operational Earnings Per Share of $11.30 - $11.50 or 4.7% - 6.7% was provided on our Q1 2026 Earnings Call. For your convenience, the final Q1 2026 earnings transcript and presentation are attached. Full Q1 2026 earnings call operational commentary and key drivers can be listened to here and the Q1 2026 10-Q can be found here. • Q2 2025 earnings call: For ease of reference, below are related sales and EPS absolute figures and growth rates for Q2 2025. Full Q2 2025 operational commentary, key drivers, and one-timers can be listened to here and the Q2 2025 10-Q can be found here. For your convenience, the final Q2 2025 earnings transcript and presentation are attached. Q2 2025: o Enterprise: $23.7B, 4.6% operational sales growth and 3.0% adjusted operational sales growth  Enterprise sales highlights can be found on page 5 of the final Q2 2025 earnings transcript attached  P&L highlights can be found on page 6 of the final Q2 2025 earnings transcript attached o Innovative Medicine: $15.2B, 3.8% operational sales growth  Innovative Medicine sales highlights can be found on page 5-6 of the final Q2 2025 earnings transcript attached o MedTech: $8.5B, 6.1% operational sales growth  MedTech sales highlights can be found on page 6 of the final Q2 2025 earnings transcript attached -- 4 of 6 -- 1 Other segment items for each reportable segment include charges related to other income and expenses, restructuring activities and impairment charges related to in-process research and development 2 Non-GAAP measure; excludes intangible amortization expense and special items; see reconciliation schedules on the Investor Relations section of the company's website 2025 (Unaudited; Dollar in millions) Earnings before provision for taxes on income by segment 1 Innovative Medicine Amount % to Sales Amount % to Sales Amount % to Sale s Amount % to Sales Amount % to Sales Sales to customers $1 3,873 1 00.0 $1 5,202 1 00.0 $1 5,563 1 00.0 $1 5,763 1 00.0 $60,401 1 00.0 Cost of products sold (COGS) 4,020 29.0 3,978 26.2 3,672 23.6 3,976 25.2 1 5,646 25.9 Selling, marketing and administrative expenses (SM&A) 2,261 1 6.3 2,789 1 8.3 2,869 1 8.5 3,456 21 .9 1 1 ,375 1 8.8 Research and development expense (R&D)* 2,548 1 8.4 2,869 1 8.9 2,944 1 8.9 3,466 22.0 1 1 ,827 1 9.6 Other segment items 1 (1 66) (1 .2) 1 4 0.1 (368) (2.4) (1 93) (1 .2) (71 3) (1 .2) Adjusted segment income before tax 2 $5,21 0 37.5 $5,552 36.5 $6,446 41 .4 $5,058 32.1 $22,266 36.9 Amount % to Sales Amount % to Sales Amount % to Sale s Amount % to Sales Amount % to Sales Sales to customers $1 3,873 1 00.0 $1 5,202 1 00.0 $1 5,563 1 00.0 $1 5,763 1 00.0 $60,401 1 00.0 Cost of products sold (COGS) 3,371 24.3 3,1 80 20.9 3,093 1 9.9 3,261 20.7 1 2,905 21 .4 Selling, marketing and administrative expenses (SM&A) 2,261 1 6.3 2,789 1 8.3 2,869 1 8.4 3,456 21 .9 1 1 ,375 1 8.8 Research and development expense (R&D)* 2,548 1 8.4 2,869 1 8.9 2,944 1 8.9 3,466 22.0 1 1 ,827 1 9.6 Other segment items 1 (204) (1 .5) (1 29) (0.8) (238) (1 .5) (1 35) (0.9) (706) (1 .2) Adjusted segment income before tax 2 $5,897 42.5 $6,493 42.7 $6,895 44.3 $5,71 5 36.3 $25,000 41 .4 As reported Q1 Q2 Q3 Q4 YTD Adjusted Q1 Q2 Q3 Q4 YTD -- 5 of 6 -- 1 Other segment items for each reportable segment include charges related to other income and expenses, restructuring activities and impairment charges related to in-process research and development 2 Non-GAAP measure; excludes intangible amortization expense and special items; see reconciliation schedules on the Investor Relations section of the company's website 2025 (Unaudited; Dollar in millions) Earnings before provision for taxes on income by segment 2 MedTech Amount % to Sale s Amount % to Sales Amount % to Sales Amount % to Sales Amount % to Sales Sales to customers $8,020 1 00.0 $8,541 1 00.0 $8,430 1 00.0 $8,801 1 00.0 $33,792 1 00.0 Cost of products sold (COGS) 3,326 41 .5 3,638 42.6 3,61 2 42.9 3,973 45.1 1 4,549 43.1 Selling, marketing and administrative expenses (SM&A) 2,656 33.1 2,862 33.5 2,801 33.2 3,035 34.5 1 1 ,354 33.6 Research and development expense (R&D)* 677 8.4 647 7.6 728 8.6 786 8.9 2,838 8.4 Other segment items 1 (60) (0.7) 1 90 2.2 2 - 806 9.2 938 2.8 Adjusted segment income before tax 2 $1 ,421 1 7.7 $1 ,204 1 4.1 $1 ,287 1 5.3 $201 2.3 $4,1 1 3 1 2.1 Amount % to Sale s Amount % to Sales Amount % to Sales Amount % to Sales Amount % to Sales Sales to customers $8,020 1 00.0 $8,541 1 00.0 $8,430 1 00.0 $8,801 1 00.0 $33,792 1 00.0 Cost of products sold (COGS) 2,795 34.8 3,1 42 36.8 3,1 1 9 37.0 3,435 39.0 1 2,491 37.0 Selling, marketing and administrative expenses (SM&A) 2,656 33.1 2,862 33.5 2,801 33.2 3,035 34.5 1 1 ,354 33.6 Research and development expense (R&D)* 671 8.4 690 8.1 728 8.6 786 8.9 2,875 8.5 Other segment items 1 (1 82) (2.2) (53) (0.6) 1 5 0.2 1 0 0.2 (21 0) (0.6) Adjusted segment income before tax 2 $2,080 25.9 $1 ,900 22.2 $1 ,767 21 .0 $1 ,535 1 7.4 $7,282 21 .5 As reported Q1 YTD Adjusted Q1 YTD Q2 Q2 Q3 Q3 Q4 Q4 -- 6 of 6 --